

Pierre Hainaut

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3019289/publications.pdf>

Version: 2024-02-01

367
papers

33,654
citations

4136

87
h-index

4880

168
g-index

379
all docs

379
docs citations

379
times ranked

40983
citing authors

#	ARTICLE	IF	CITATIONS
1	A global view of hepatocellular carcinoma: trends, risk, prevention and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 589-604.	8.2	2,482
2	TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. <i>Cold Spring Harbor Perspectives in Biology</i> , 2010, 2, a001008-a001008.	2.3	1,494
3	Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. <i>Human Mutation</i> , 2007, 28, 622-629.	1.1	1,441
4	A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. <i>Nature</i> , 2008, 452, 633-637.	13.7	1,169
5	The IARC TP53 database: New online mutation analysis and recommendations to users. <i>Human Mutation</i> , 2002, 19, 607-614.	1.1	1,107
6	Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. <i>Oncogene</i> , 2002, 21, 7435-7451.	2.6	961
7	p53 and Human Cancer: The First Ten Thousand Mutations. <i>Advances in Cancer Research</i> , 1999, 77, 81-137.	1.9	805
8	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. <i>Oncogene</i> , 2007, 26, 2157-2165.	2.6	796
9	PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain. <i>Cancer Cell</i> , 2009, 15, 376-388.	7.7	508
10	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.. <i>Clinical Cancer Research</i> , 2006, 12, 1157-1167.	3.2	495
11	Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers. <i>Science Translational Medicine</i> , 2013, 5, 186ra66.	5.8	392
12	Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. <i>Mutation Research - Reviews in Mutation Research</i> , 2007, 635, 105-117.	2.4	388
13	IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. <i>Nucleic Acids Research</i> , 1998, 26, 205-213.	6.5	387
14	Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. <i>Cancer Research</i> , 2003, 63, 6643-50.	0.4	350
15	Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. <i>BMJ: British Medical Journal</i> , 2010, 340, b5500-b5500.	2.4	342
16	Patterns of p53 G->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. <i>Carcinogenesis</i> , 2001, 22, 367-374.	1.3	332
17	Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. <i>Nucleic Acids Research</i> , 1997, 25, 151-157.	6.5	301
18	Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. <i>Nucleic Acids Research</i> , 2006, 34, 1317-1325.	6.5	295

#	ARTICLE	IF	CITATIONS
19	IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines. <i>Human Mutation</i> , 1999, 14, 1-8.	1.1	282
20	Pooled Analysis of the Prognostic and Predictive Effects of <i>KRAS</i> Mutation Status and <i>KRAS</i> Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2173-2181.	0.8	270
21	Identification of osteopontin as a novel marker for early hepatocellular carcinoma. <i>Hepatology</i> , 2012, 55, 483-490.	3.6	268
22	TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers. <i>Cancer Research</i> , 2005, 65, 5076-5083.	0.4	237
23	Hepatocellular Carcinoma: From Gene to Public Health. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1844-1851.	3.0	234
24	Quantitative Analysis of DNA Methylation Profiles in Lung Cancer Identifies Aberrant DNA Methylation of Specific Genes and Its Association with Gender and Cancer Risk Factors. <i>Cancer Research</i> , 2009, 69, 243-252.	0.4	231
25	δ -N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. <i>Oncogene</i> , 2002, 21, 6722-6728.	2.6	229
26	Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. <i>Oncogene</i> , 2000, 19, 5227-5236.	2.6	221
27	Targeting the hallmarks of cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 50-51.	1.1	209
28	Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. <i>Molecular Oncology</i> , 2007, 1, 26-41.	2.1	206
29	Biospecimen Reporting for Improved Study Quality (BRISQ). <i>Journal of Proteome Research</i> , 2011, 10, 3429-3438.	1.8	205
30	Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. <i>Tobacco Control</i> , 2008, 17, 132-141.	1.8	204
31	Genetics of lung-cancer susceptibility. <i>Lancet Oncology</i> , The, 2011, 12, 399-408.	5.1	191
32	Sarcomas in <i>TP53</i> germline mutation carriers. <i>Cancer</i> , 2012, 118, 1387-1396.	2.0	189
33	G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. <i>Carcinogenesis</i> , 2011, 32, 271-278.	1.3	186
34	Tumor-cell-derived microvesicles as carriers of molecular information in cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 66-75.	1.1	185
35	The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. <i>Hepatology</i> , 2004, 39, 211-219.	3.6	184
36	Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2008, 99, 143-150.	2.9	183

#	ARTICLE	IF	CITATIONS
37	Genetic steps in the development of squamous cell carcinoma of the esophagus. <i>Mutation Research - Reviews in Mutation Research</i> , 2000, 462, 335-342.	2.4	176
38	Somatic TP53 Mutations in the Era of Genome Sequencing. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026179.	2.9	176
39	Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. <i>Cell Death and Differentiation</i> , 2011, 18, 1815-1824.	5.0	173
40	New approaches to understanding p53 gene tumor mutation spectra. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1999, 431, 199-209.	0.4	171
41	The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. <i>Cancer Letters</i> , 2007, 245, 96-102.	3.2	170
42	Regulation of p53 by Metal Ions and by Antioxidants: Dithiocarbamate Down-Regulates p53 DNA-Binding Activity by Increasing the Intracellular Level of Copper. <i>Molecular and Cellular Biology</i> , 1997, 17, 5699-5706.	1.1	169
43	Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. <i>Diabetologia</i> , 2011, 54, 2272-2282.	2.9	169
44	Cadmium Induces Conformational Modifications of Wild-type p53 and Suppresses p53 Response to DNA Damage in Cultured Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 31663-31670.	1.6	168
45	Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. <i>Obesity Reviews</i> , 2013, 14, 665-678.	3.1	168
46	Ser-249 p53 Mutations in Plasma DNA of Patients With Hepatocellular Carcinoma From The Gambia. <i>Journal of the National Cancer Institute</i> , 2000, 92, 148-153.	3.0	167
47	Zinc Binding and Redox Control of p53 Structure and Function. <i>Antioxidants and Redox Signaling</i> , 2001, 3, 611-623.	2.5	167
48	Biospecimen reporting for improved study quality (BRISQ). <i>Cancer Cytopathology</i> , 2011, 119, 92-102.	1.4	167
49	Redox signalling and transition metals in the control of the p53 pathway. <i>Biochemical Pharmacology</i> , 2000, 59, 25-33.	2.0	159
50	249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. <i>Oncogene</i> , 2005, 24, 5858-5867.	2.6	159
51	TP53: a key gene in human cancer. <i>Biochimie</i> , 2002, 84, 83-93.	1.3	158
52	Air pollution and risk of lung cancer in a prospective study in Europe. <i>International Journal of Cancer</i> , 2006, 119, 169-174.	2.3	158
53	TP53 and KRAS2 Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study. <i>Cancer Research</i> , 2006, 66, 6871-6876.	0.4	158
54	Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. <i>Journal of Hepatology</i> , 2011, 54, 705-715.	1.8	153

#	ARTICLE	IF	CITATIONS
55	Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. <i>Cancer Gene Therapy</i> , 2011, 18, 2-11.	2.2	151
56	Genotoxic and non-genotoxic pathways of p53 induction. <i>Cancer Letters</i> , 2001, 174, 1-15.	3.2	144
57	Mechanical Stress-Induced DNA damage and Rac38MAPK Signal Pathways Mediate p53-dependent Apoptosis in Vascular Smooth Muscle Cells. <i>FASEB Journal</i> , 2002, 16, 1423-1425.	0.2	144
58	Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. <i>Endocrine-Related Cancer</i> , 2010, 17, 1007-1019.	1.6	143
59	Cadmium in the Environment: Sources, Mechanisms of Biototoxicity, and Biomarkers. <i>Reviews on Environmental Health</i> , 2000, 15, 299-323.	1.1	141
60	Recent advances in p53 research: an interdisciplinary perspective. <i>Cancer Gene Therapy</i> , 2009, 16, 1-12.	2.2	140
61	Toward a roadmap in global biobanking for health. <i>European Journal of Human Genetics</i> , 2012, 20, 1105-1111.	1.4	139
62	Epidemiology of oesophagogastric cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 921-945.	1.0	137
63	Natural variations of copper and sulfur stable isotopes in blood of hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 982-985.	3.3	133
64	Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2011, 6, e26315.	1.1	132
65	Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. <i>Current Opinion in Oncology</i> , 2018, 30, 23-29.	1.1	129
66	Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. <i>Human Mutation</i> , 2002, 19, 149-164.	1.1	122
67	MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2010, 70, 8288-8298.	0.4	121
68	Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. <i>Human Mutation</i> , 2010, 31, 143-150.	1.1	116
69	Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Non-Small Cell Lung Cancers in Relation to Smoking History. <i>Cancer Research</i> , 2007, 67, 5667-5672.	0.4	111
70	The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy. <i>Cancer Letters</i> , 2009, 286, 29-37.	3.2	111
71	Massively regulated genes: the example of TP53. <i>Journal of Pathology</i> , 2010, 220, 164-173.	2.1	111
72	Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. <i>Oncogene</i> , 2005, 24, 3853-3863.	2.6	110

#	ARTICLE	IF	CITATIONS
73	DNA Adducts and Lung Cancer Risk: A Prospective Study. <i>Cancer Research</i> , 2005, 65, 8042-8048.	0.4	109
74	Biospecimen Reporting for Improved Study Quality. <i>Biopreservation and Biobanking</i> , 2011, 9, 57-70.	0.5	106
75	A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database.. <i>Environmental Health Perspectives</i> , 1998, 106, 385-391.	2.8	105
76	PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 882-889.	0.6	105
77	Skin human papillomavirus type 38 alters p53 functions by accumulation of ^{125}I Np73. <i>EMBO Reports</i> , 2006, 7, 334-340.	2.0	101
78	p53 protein variants: structural and functional similarities with p63 and p73 isoforms. <i>Oncogene</i> , 2004, 23, 631-638.	2.6	100
79	Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. , 1998, 21, 205-214.		98
80	Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 5503-5508.	3.3	98
81	Human Papillomavirus Type 16 and TP53 Mutation in Oral Cancer. <i>Cancer Research</i> , 2004, 64, 468-471.	0.4	98
82	Amount of DNA in plasma and cancer risk: A prospective study. <i>International Journal of Cancer</i> , 2004, 111, 746-749.	2.3	95
83	Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. <i>Oncogene</i> , 2010, 29, 1329-1338.	2.6	95
84	TP53 mutations in squamous-cell carcinomas of the conjunctiva: evidence for UV-induced mutagenesis. <i>Mutagenesis</i> , 2004, 19, 399-401.	1.0	94
85	Hepatocellular Carcinoma and Polymorphisms in Carcinogen-Metabolizing and DNA Repair Enzymes in a Population with Aflatoxin Exposure and Hepatitis B Virus Endemicity. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 373-379.	1.1	94
86	Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. <i>Cancer Letters</i> , 2008, 261, 21-25.	3.2	94
87	Prognostic value of <i>TP53</i> , <i>KRAS</i> and <i>EGFR</i> mutations in nonsmall cell lung cancer: the EU-ELC cohort. <i>European Respiratory Journal</i> , 2012, 40, 177-184.	3.1	92
88	Mutant p53 targeting by the low molecular weight compound STIMA-4. <i>Molecular Oncology</i> , 2008, 2, 70-80.	2.1	91
89	Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. <i>Current Opinion in Oncology</i> , 2010, 22, 64-69.	1.1	91
90	Pooled Analysis of the Prognostic and Predictive Effects of <i>TP53</i> Comutation Status Combined With <i>KRAS</i> or <i>EGFR</i> Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2018-2027.	0.8	91

#	ARTICLE	IF	CITATIONS
91	Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2009, 15, 7719-7725.	3.2	87
92	Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. <i>Journal of Viral Hepatitis</i> , 2010, 17, 115-122.	1.0	86
93	Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. <i>International Journal of Cancer</i> , 2004, 110, 374-379.	2.3	85
94	Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms. <i>Npj Systems Biology and Applications</i> , 2018, 4, 21.	1.4	84
95	TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC (International Agency for Research on Cancer) Scientific Publications, 2004, , 247-70.	0.4	83
96	BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. , 2000, 27, 57-64.		81
97	Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with p73. <i>Carcinogenesis</i> , 2008, 29, 273-281.	1.3	81
98	Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran. <i>Gut</i> , 2010, 59, 1178-1183.	6.1	80
99	The role of the pathologist in tissue banking: European Consensus Expert Group Report. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 449-454.	1.4	79
100	Role of Obesity in the Risk of Breast Cancer: Lessons from Anthropometry. <i>Journal of Oncology</i> , 2013, 2013, 1-19.	0.6	79
101	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 850-861.	0.5	78
102	Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. <i>Journal of Clinical Investigation</i> , 2010, 120, 3663-3667.	3.9	77
103	Long-Term Protection against HBV Chronic Carriage of Gambian Adolescents Vaccinated in Infancy and Immune Response in HBV Booster Trial in Adolescence. <i>PLoS ONE</i> , 2007, 2, e753.	1.1	76
104	The tumor suppressor protein p53. <i>Current Opinion in Oncology</i> , 1995, 7, 76-82.	1.1	75
105	Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. <i>Molecular Carcinogenesis</i> , 2002, 33, 181-188.	1.3	74
106	On the origin of G to T transversions in lung cancer. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2003, 526, 39-43.	0.4	73
107	Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. <i>International Journal of Cancer</i> , 2007, 121, 929-937.	2.3	73
108	p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. <i>Cancer Letters</i> , 2005, 217, 221-230.	3.2	71

#	ARTICLE	IF	CITATIONS
109	Nitric Oxide Nitrates Tyrosine Residues of Tumor-Suppressor p53 Protein in MCF-7 Cells. <i>Biochemical and Biophysical Research Communications</i> , 2000, 267, 609-613.	1.0	70
110	Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. <i>Cancer Letters</i> , 2009, 286, 80-88.	3.2	70
111	In Vitro Recapitulating of TP53 Mutagenesis in Hepatocellular Carcinoma Associated With Dietary Aflatoxin B1 Exposure. <i>Gastroenterology</i> , 2009, 137, 1127-1137.e5.	0.6	69
112	p53 isoforms - A conspiracy to kidnap p53 tumor suppressor activity?. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 391-406.	2.4	68
113	Physical activity reduces the risk of incident type 2 diabetes in general and in abdominally lean and obese men and women: the EPICâ€™InterAct Study. <i>Diabetologia</i> , 2012, 55, 1944-1952.	2.9	68
114	Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. <i>Genes and Development</i> , 2016, 30, 772-785.	2.7	68
115	Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice. <i>Cancer Research</i> , 2017, 77, 1250-1260.	0.4	68
116	Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?. <i>Lancet Oncology</i> , The, 2009, 10, 920-925.	5.1	67
117	<i>KRAS</i> mutation status in primary nonsmall cell lung cancer and matched metastases. <i>Cancer</i> , 2010, 116, 2682-2687.	2.0	67
118	Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging. <i>Cancer</i> , 2017, 123, 4207-4214.	2.0	66
119	Variable population prevalence estimates of germline <i>TP53</i> variants: A gnomAD-based analysis. <i>Human Mutation</i> , 2019, 40, 97-105.	1.1	66
120	TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. <i>Journal of Medical Genetics</i> , 2009, 46, 766-772.	1.5	64
121	Infection with Hepatitis B and C Viruses and Risk of Lymphoid Malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 208-214.	1.1	64
122	Inactivation of the p53 protein in cell lines derived from human esophageal cancers. <i>International Journal of Cancer</i> , 1997, 71, 79-87.	2.3	63
123	The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. <i>Oncogene</i> , 2000, 19, 1206-1214.	2.6	63
124	20 Years into the Gambia Hepatitis Intervention Study: Assessment of Initial Hypotheses and Prospects for Evaluation of Protective Effectiveness Against Liver Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3216-3223.	1.1	63
125	30 years and a long way into p53 research. <i>Lancet Oncology</i> , The, 2009, 10, 913-919.	5.1	63
126	Aberrant DNA Methylation Links Cancer Susceptibility Locus 15q25.1 to Apoptotic Regulation and Lung Cancer. <i>Cancer Research</i> , 2010, 70, 2779-2788.	0.4	62

#	ARTICLE	IF	CITATIONS
127	Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). <i>Cancer Letters</i> , 2011, 311, 85-95.	3.2	62
128	Tumor necrosis factor (TNF)- α , soluble TNF receptors and endometrial cancer risk: The EPIC study. <i>International Journal of Cancer</i> , 2011, 129, 2032-2037.	2.3	61
129	TP53 and mutations in human cancer.. <i>Acta Biochimica Polonica</i> , 2003, 50, 231-238.	0.3	61
130	Insulin binding to its receptor induces a conformational change in the receptor C-terminus. <i>Biochemistry</i> , 1990, 29, 4634-4641.	1.2	60
131	p53 regulates the transcription of its β 133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. <i>Oncogene</i> , 2010, 29, 2691-2700.	2.6	60
132	Extremely High Tp53 Mutation Load in Esophageal Squamous Cell Carcinoma in Golestan Province, Iran. <i>PLoS ONE</i> , 2011, 6, e29488.	1.1	60
133	Molecular and Clinical Differences between Adenocarcinomas of the Esophagus and of the Gastric Cardia. <i>American Journal of Pathology</i> , 2001, 158, 33-40.	1.9	59
134	Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran. <i>Oncogene</i> , 2001, 20, 7368-7374.	2.6	59
135	Aflatoxin Exposure and Viral Hepatitis in the Etiology of Liver Cirrhosis in The Gambia, West Africa. <i>Environmental Health Perspectives</i> , 2008, 116, 1553-1557.	2.8	59
136	An Empirical Validation of the Within-subject Biospecimens Pooling Approach to Minimize Exposure Misclassification in Biomarker-based Studies. <i>Epidemiology</i> , 2019, 30, 756-767.	1.2	59
137	Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. <i>Oncogene</i> , 2001, 20, 3533-3540.	2.6	57
138	TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. <i>Seminars in Cancer Biology</i> , 2001, 11, 353-360.	4.3	56
139	Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. <i>Oncogene</i> , 2006, 25, 5708-5718.	2.6	56
140	Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0174265.	1.1	56
141	Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. <i>Carcinogenesis</i> , 2010, 31, 1475-1482.	1.3	55
142	DNA Methylation of Hepatitis B Virus (HBV) Genome Associated with the Development of Hepatocellular Carcinoma and Occult HBV Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, 700-704.	1.9	55
143	PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. <i>Investigational New Drugs</i> , 2014, 32, 783-794.	1.2	55
144	A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3248-3260.	2.7	55

#	ARTICLE	IF	CITATIONS
145	Analysis of the Li-Fraumeni Spectrum Based on an International Germline <i>TP53</i> Variant Data Set. <i>JAMA Oncology</i> , 2021, 7, 1800.	3.4	55
146	International Efforts to Develop Biospecimen Best Practices. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 912-915.	1.1	54
147	Osteopontin and latent-TGF β 2 binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 136, 172-181.	2.3	54
148	Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 1121-1131.	0.4	53
149	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. <i>Cell Death and Differentiation</i> , 2022, 29, 1071-1073.	5.0	53
150	Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. <i>Cancer Letters</i> , 2001, 162, 231-235.	3.2	52
151	Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in) <i>TJ ETQq1 1 0.784314 rgB1 /Overfoc</i> 1896-1815	1.1	52
152	An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2976-2986.	3.2	52
153	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <i>Breast Cancer Research</i> , 2012, 14, R70.	2.2	52
154	Quantitative analysis of DNA methylation after whole bisulfite amplification of a minute amount of DNA from body fluids. <i>Epigenetics</i> , 2009, 4, 221-230.	1.3	51
155	Control of hepatocellular carcinoma through Hepatitis B vaccination in areas of high endemicity: Perspectives for global liver cancer prevention. <i>Cancer Letters</i> , 2009, 286, 15-21.	3.2	50
156	Characteristics of never smoker lung cancer including environmental and occupational risk factors. <i>Lung Cancer</i> , 2010, 67, 144-150.	0.9	50
157	Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil. <i>PLoS ONE</i> , 2014, 9, e99893.	1.1	49
158	Temperature sensitivity for conformation is an intrinsic property of wild-type p53. <i>British Journal of Cancer</i> , 1995, 71, 227-231.	2.9	48
159	Redox Control and Interplay Between p53 Isoforms: Roles in the Regulation of Basal p53 Levels, Cell Fate, and Senescence. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1655-1667.	2.5	48
160	Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. <i>Liver International</i> , 2011, 31, 215-221.	1.9	48
161	TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. <i>British Journal of Cancer</i> , 2001, 85, 721-726.	2.9	47
162	TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. <i>Mutagenesis</i> , 2001, 16, 551-553.	1.0	47

#	ARTICLE	IF	CITATIONS
163	<i>TP53 R249S</i> Mutations, Exposure to Aflatoxin, and Occurrence of Hepatocellular Carcinoma in a Cohort of Chronic Hepatitis B Virus Carriers from Qidong, China. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1638-1643.	1.1	47
164	Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. <i>Tumor Biology</i> , 2012, 33, 325-336.	0.8	47
165	Drosophila p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation. <i>Cell Death and Differentiation</i> , 2013, 20, 108-116.	5.0	47
166	Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. <i>Human Mutation</i> , 2004, 24, 21-34.	1.1	46
167	Mistaken Identity of Widely Used Esophageal Adenocarcinoma Cell Line TE-7. <i>Cancer Research</i> , 2007, 67, 7996-8001.	0.4	46
168	Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. <i>Molecular Carcinogenesis</i> , 2008, 47, 275-285.	1.3	46
169	Effects of $\Delta 40p53$, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. <i>BMC Cancer</i> , 2013, 13, 134.	1.1	46
170	Cytokeratin Expression in Adenocarcinomas of the Esophagogastric Junction. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1213-1221.	2.1	44
171	Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G45-G53.	1.6	44
172	Curbing the liver cancer epidemic in Africa. <i>Lancet, The</i> , 2008, 371, 367-368.	6.3	44
173	Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity. <i>Clinical Cancer Research</i> , 2014, 20, 5777-5786.	3.2	44
174	ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 116, 15-24.	0.9	44
175	Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. <i>Cancer Letters</i> , 2008, 264, 201-208.	3.2	43
176	Mutant p53 rescue and modulation of p53 redox state. <i>Cell Cycle</i> , 2009, 8, 2509-2517.	1.3	43
177	Methylation patterns in sentinel genes in peripheral blood cells of heavy smokers: Influence of cruciferous vegetables in an intervention study. <i>Epigenetics</i> , 2011, 6, 1114-1119.	1.3	43
178	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. <i>European Respiratory Journal</i> , 2012, 39, 172-179.	3.1	43
179	A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. <i>Cell Death and Disease</i> , 2013, 4, e492-e492.	2.7	43
180	The Cytoprotective Aminothiols WR1065 Activates p53 through a Non-genotoxic Signaling Pathway Involving c-Jun N-terminal Kinase. <i>Journal of Biological Chemistry</i> , 2003, 278, 11879-11887.	1.6	42

#	ARTICLE	IF	CITATIONS
181	The expression of TA and p53 are regulated by different mechanisms in liver cells. <i>Oncogene</i> , 2005, 24, 512-519.	2.6	42
182	Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis. <i>PLoS ONE</i> , 2012, 7, e37707.	1.1	42
183	Smoky coal exposure, NBS1 polymorphisms, p53 protein accumulation, and lung cancer risk in Xuan Wei, China. <i>Lung Cancer</i> , 2005, 49, 317-323.	0.9	41
184	Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. <i>Cancer Prevention Research</i> , 2016, 9, 758-765.	0.7	41
185	Quantitative Analysis of Plasma TP53 249Ser-Mutated DNA by Electrospray Ionization Mass Spectrometry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2956-2962.	1.1	40
186	Human tissue biobanks as instruments for drug discovery and development: impact on personalized medicine. <i>Biomarkers in Medicine</i> , 2010, 4, 895-903.	0.6	40
187	Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. <i>Human Mutation</i> , 2017, 38, 1723-1730.	1.1	40
188	Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. <i>Cancer</i> , 1996, 66, 301-304.		39
189	CHRNA5 as negative regulator of nicotine signaling in normal and cancer bronchial cells: effects on motility, migration and p63 expression. <i>Carcinogenesis</i> , 2011, 32, 1388-1395.	1.3	39
190	Breast cancer in pre-menopausal women in West Africa: Analysis of temporal trends and evaluation of risk factors associated with reproductive life. <i>Breast</i> , 2013, 22, 828-835.	0.9	39
191	Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil. <i>Cancer</i> , 2013, 119, 4341-4349.	2.0	39
192	Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	39
193	TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. <i>Carcinogenesis</i> , 2012, 33, 1219-1224.	1.3	38
194	TP53 PIN3 and PEX4 polymorphisms and infertility associated with endometriosis or with post-in vitro fertilization implantation failure. <i>Cell Death and Disease</i> , 2012, 3, e392-e392.	2.7	37
195	Interferon-inducible guanylate binding protein (GBP2): A novel p53-regulated tumor marker in esophageal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2009, 124, 272-279.	2.3	36
196	A Common Molecular Mechanism Underlies Two Phenotypically Distinct 17p13.1 Microdeletion Syndromes. <i>American Journal of Human Genetics</i> , 2010, 87, 631-642.	2.6	36
197	Transcription factor E4F1 is essential for epidermal stem cell maintenance and skin homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 21076-21081.	3.3	36
198	Next-generation sequencing: emerging lessons on the origins of human cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 62-68.	1.1	36

#	ARTICLE	IF	CITATIONS
199	Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. <i>Molecular Oncology</i> , 2014, 8, 555-564.	2.1	36
200	Biobanking in a Fast Moving World: An International Perspective. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 50-51.	0.9	35
201	The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026153.	2.9	35
202	Deciphering the Impact of Early-Life Exposures to Highly Variable Environmental Factors on Foetal and Child Health: Design of SEPAGES Couple-Child Cohort. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3888.	1.2	35
203	TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child - evidence for chimerism involving a common mutant founder haplotype: case report. <i>BMC Cancer</i> , 2011, 11, 449.	1.1	34
204	Anthropometry, Silhouette Trajectory, and Risk of Breast Cancer in Mexican Women. <i>American Journal of Preventive Medicine</i> , 2014, 46, S52-S64.	1.6	34
205	Seasonal Variation in TP53 R249S-Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection. <i>Environmental Health Perspectives</i> , 2011, 119, 1635-1640.	2.8	33
206	Breast cancer in Latin America: global burden, patterns, and risk factors. <i>Salud Publica De Mexico</i> , 2014, 56, 547.	0.1	33
207	Hepatitis B surface antigenaemia and alpha-foetoprotein detection from dried blood spots: applications to field-based studies and to clinical care in hepatitis B virus endemic areas. <i>Journal of Viral Hepatitis</i> , 2005, 12, 642-647.	1.0	32
208	4-Aminobiphenyl-Hemoglobin Adducts and Risk of Smoking-Related Disease in Never Smokers and Former Smokers in the European Prospective Investigation into Cancer and Nutrition Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2118-2124.	1.1	32
209	Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia. <i>BMC Cancer</i> , 2012, 12, 602.	1.1	32
210	Wnt/ β -catenin signaling pathway in hepatocellular carcinomas cases from Colombia. <i>Annals of Hepatology</i> , 2015, 14, 64-74.	0.6	32
211	Viral strategies for circumventing p53: the case of severe acute respiratory syndrome coronavirus. <i>Current Opinion in Oncology</i> , 2021, 33, 149-158.	1.1	32
212	The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2004, 41, 551-583.	2.7	31
213	Sources of Pre-Analytical Variations in Yield of DNA Extracted from Blood Samples: Analysis of 50,000 DNA Samples in EPIC. <i>PLoS ONE</i> , 2012, 7, e39821.	1.1	31
214	Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis. <i>Proceedings of the Nutrition Society</i> , 1999, 58, 565-571.	0.4	30
215	Surface functionalization of gold nanoclusters with arginine: a trade-off between microtumor uptake and radiotherapy enhancement. <i>Nanoscale</i> , 2020, 12, 6959-6963.	2.8	30
216	Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 11145-11158.	0.8	30

#	ARTICLE	IF	CITATIONS
217	Antibodies to phosphotyrosine injected in <i>Xenopus laevis</i> oocytes modulate maturation induced by insulin/IGF-I. <i>Experimental Cell Research</i> , 1991, 195, 129-136.	1.2	29
218	Analysis of p53, p16MTS1, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines. <i>British Journal of Cancer</i> , 1998, 77, 1573-1579.	2.9	29
219	TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in South Thailand. <i>International Journal of Cancer</i> , 2000, 88, 223-227.	2.3	29
220	p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. <i>International Journal of Cancer</i> , 2011, 128, 1813-1821.	2.3	29
221	Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15497-15501.	3.3	29
222	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. <i>Carcinogenesis</i> , 2014, 35, 807-815.	1.3	29
223	Activation of p53 by the cytoprotective aminothiols WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. <i>Biochemical Pharmacology</i> , 2003, 65, 1129-1137.	2.0	28
224	In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. <i>Carcinogenesis</i> , 2008, 29, 1428-1434.	1.3	28
225	Pharmacological rescue of p53 in cancer cells: The soloist meets the PRIMA donna. <i>Cell Cycle</i> , 2011, 10, 879-878.	1.3	28
226	TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma. <i>Cancer Letters</i> , 2009, 275, 234-239.	3.2	27
227	Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 35-42.	1.1	27
228	Impact of Delay to Cryopreservation on RNA Integrity and Genome-Wide Expression Profiles in Resected Tumor Samples. <i>PLoS ONE</i> , 2013, 8, e79826.	1.1	27
229	Tumor-specific mutations in p53: The acid test. <i>Nature Medicine</i> , 2002, 8, 21-23.	15.2	26
230	Increase in Female Liver Cancer in The Gambia, West Africa: Evidence from 19 Years of Population-Based Cancer Registration (1988-2006). <i>PLoS ONE</i> , 2011, 6, e18415.	1.1	26
231	TP63 P2 promoter functional analysis identifies β -catenin as a key regulator of β -Np63 expression. <i>Oncogene</i> , 2011, 30, 4656-4665.	2.6	26
232	Interactions between hepatitis B virus and aflatoxin B1: effects on p53 induction in HepaRG cells. <i>Journal of General Virology</i> , 2012, 93, 640-650.	1.3	26
233	Premalignant lesions of the esophagogastric mucosa. <i>Seminars in Oncology</i> , 2004, 31, 498-512.	0.8	25
234	p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. <i>Cancer Letters</i> , 2011, 300, 215-224.	3.2	25

#	ARTICLE	IF	CITATIONS
235	Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts. <i>Carcinogenesis</i> , 2014, 35, 2706-2715.	1.3	25
236	Aminothiols WR1065 induces differential gene expression in the presence of wild-type p53. <i>Oncogene</i> , 2005, 24, 3964-3975.	2.6	24
237	TP53 and EGFR mutations in combination with lifestyle risk factors in tumours of the upper aerodigestive tract from South America. <i>Carcinogenesis</i> , 2010, 31, 1054-1059.	1.3	24
238	Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. <i>Cancer Research</i> , 2002, 62, 2897-905.	0.4	24
239	Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma. <i>Sarcoma</i> , 2012, 2012, 1-6.	0.7	23
240	Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. <i>Cancer Letters</i> , 2013, 331, 46-51.	3.2	23
241	Nitric Oxide Prevents $\hat{3}$ -Radiation-Induced Cell Cycle Arrest by Impairing p53 Function in MCF-7 Cells. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 766-771.	1.0	22
242	Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. <i>Annals of Hepatology</i> , 2008, 7, 339-344.	0.6	22
243	Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. <i>Cancer Letters</i> , 2009, 279, 57-64.	3.2	22
244	Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. <i>Cell Cycle</i> , 2012, 11, 4570-4578.	1.3	22
245	A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 17-22.	1.4	22
246	Dietary Carbohydrate, Glycemic Index, Glycemic Load, and Breast Cancer Risk Among Mexican Women. <i>Epidemiology</i> , 2015, 26, 917-924.	1.2	22
247	Sources of bias in the detection and reporting of p53 mutations in human cancer: analysis of the IARC p53 mutation database. <i>Genetic Analysis, Techniques and Applications</i> , 1999, 14, 229-233.	1.5	21
248	Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. <i>Human Mutation</i> , 2006, 27, 163-172.	1.1	21
249	TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. <i>Cancer Letters</i> , 2010, 293, 92-98.	3.2	21
250	Proteomics beyond proteomics: toward clinical applications. <i>Current Opinion in Oncology</i> , 2011, 23, 77-82.	1.1	21
251	DNA methylation changes associated with risk factors in tumors of the upper aerodigestive tract. <i>Epigenetics</i> , 2012, 7, 270-277.	1.3	21
252	Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. <i>Genetics and Molecular Biology</i> , 2016, 39, 210-222.	0.6	21

#	ARTICLE	IF	CITATIONS
253	Increased Oxidative Damage in Carriers of the Germline TP53 p.R337H Mutation. <i>PLoS ONE</i> , 2012, 7, e47010.	1.1	21
254	TP53 mutations, human papilloma virus DNA and inflammation markers in esophageal squamous cell carcinoma from the Rift Valley, a high-incidence area in Kenya. <i>BMC Research Notes</i> , 2011, 4, 469.	0.6	20
255	Cancer as a metabolic disease. <i>Current Opinion in Oncology</i> , 2012, 24, 56-57.	1.1	20
256	Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27629.	0.8	20
257	Population-based breast (female) and cervix cancer rates in the Gambia: Evidence of ethnicity-related variations. <i>International Journal of Cancer</i> , 2010, 127, 2248-2256.	2.3	19
258	Mutation of TP53 and Alteration of p14arf Expression in EGFR- and KRAS-Mutated Lung Adenocarcinomas. <i>Clinical Lung Cancer</i> , 2014, 15, 124-130.	1.1	19
259	Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome. <i>Cancer Genetics</i> , 2016, 209, 97-106.	0.2	19
260	Selected technologies for measuring acquired genetic damage in humans. <i>Environmental and Molecular Mutagenesis</i> , 2010, 51, 851-870.	0.9	18
261	Intraepithelial p63-dependent expression of distinct components of cell adhesion complexes in normal esophageal mucosa and squamous cell carcinoma. <i>International Journal of Cancer</i> , 2010, 127, 2051-2062.	2.3	18
262	Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia. <i>Annals of Hepatology</i> , 2015, 14, 64-74.	0.6	18
263	Subcellular distribution of human RDM1 protein isoforms and their nucleolar accumulation in response to heat shock and proteotoxic stress. <i>Nucleic Acids Research</i> , 2007, 35, 6571-6587.	6.5	17
264	The Evolution of Tumors in Mice and Humans with Germline p53 Mutations. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2015, 80, 139-145.	2.0	17
265	Arrayed Primer Extension Resequencing of Mutations in the TP53 Tumor Suppressor Gene: Comparison with Denaturing HPLC and Direct Sequencing. <i>Clinical Chemistry</i> , 2005, 51, 1284-1287.	1.5	16
266	TP53 mutations as biomarkers for cancer epidemiology in Latin America: Current knowledge and perspectives. <i>Mutation Research - Reviews in Mutation Research</i> , 2005, 589, 192-207.	2.4	16
267	Papillomavirus infection in the conjunctiva of individuals with and without AIDS: An autopsy series from Uganda. <i>Cancer Letters</i> , 2006, 239, 98-102.	3.2	16
268	Pathology as the Cornerstone of Human Tissue Banking: European Consensus Expert Group Report. <i>Biopreservation and Biobanking</i> , 2009, 7, 157-160.	0.5	16
269	Training the Next Generation of Biobankers: A Two-Year Master's Course in the Management of Biobanks. <i>Biopreservation and Biobanking</i> , 2017, 15, 438-450.	0.5	16
270	Li-Fraumeni syndrome in a Malaysian kindred. <i>Cancer Genetics and Cytogenetics</i> , 2008, 186, 49-53.	1.0	15

#	ARTICLE	IF	CITATIONS
271	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. <i>European Respiratory Journal</i> , 2009, 34, 1477-1486.	3.1	15
272	TP53p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient. <i>BMC Cancer</i> , 2013, 13, 187.	1.1	15
273	Frequent occurrence of gastric cancer in Asian kindreds with Li-Fraumeni syndrome. <i>Clinical Genetics</i> , 2015, 88, 450-455.	1.0	15
274	Molecular Detection of Early-Stage Laryngopharyngeal Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2005, 11, 2547-2551.	3.2	14
275	Somatic mutation databases as tools for molecular epidemiology and molecular pathology of cancer: Proposed guidelines for improving data collection, distribution, and integration. <i>Human Mutation</i> , 2009, 30, 275-282.	1.1	14
276	The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: genotype-phenotype correlations. <i>Biochemical Society Transactions</i> , 2009, 37, 527-533.	1.6	14
277	Protein Profiling in Hepatocellular Carcinoma by Label-Free Quantitative Proteomics in Two West African Populations. <i>PLoS ONE</i> , 2013, 8, e68381.	1.1	14
278	Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali. <i>BMC Infectious Diseases</i> , 2015, 15, 180.	1.3	14
279	Higher forage yields under temperate drought explained by lower transpiration rates under increasing evaporative demand. <i>European Journal of Agronomy</i> , 2016, 72, 91-98.	1.9	14
280	p53, stem cell biology and childhood blastomas. <i>Current Opinion in Oncology</i> , 2019, 31, 84-91.	1.1	14
281	20-Years of Population-Based Cancer Registration in Hepatitis B and Liver Cancer Prevention in The Gambia, West Africa. <i>PLoS ONE</i> , 2013, 8, e75775.	1.1	14
282	The TP53 fertility network. <i>Genetics and Molecular Biology</i> , 2012, 35, 939-946.	0.6	14
283	Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. <i>Annals of Hepatology</i> , 2008, 7, 339-44.	0.6	14
284	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. , 2007, , 321-338.		13
285	Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand. <i>Hepatitis Research and Treatment</i> , 2011, 2011, 1-9.	2.0	13
286	18F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome. <i>Frontiers in Oncology</i> , 2015, 5, 38.	1.3	13
287	Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles. <i>BMC Cancer</i> , 2020, 20, 110.	1.1	13
288	The European Prospective Investigation into Cancer and Nutrition Biobank. <i>Methods in Molecular Biology</i> , 2011, 675, 179-191.	0.4	13

#	ARTICLE	IF	CITATIONS
289	Characterisation of human fibroblasts as keratinocyte feeder layer using p63 isoforms status. <i>Bio-Medical Materials and Engineering</i> , 2009, 19, 365-372.	0.4	12
290	Cancer Diagnostic and Predictive Biomarkers. <i>BioMed Research International</i> , 2014, 2014, 1-3.	0.9	12
291	The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 63.	1.2	12
292	LKB1 specifies neural crest cell fates through pyruvate-alanine cycling. <i>Science Advances</i> , 2019, 5, eaau5106.	4.7	12
293	Natural infection of swiss mice with Mouse Mammary Tumor Virus (MMTV): Viral expression in milk and transmission of infection. <i>Archives of Virology</i> , 1985, 83, 195-206.	0.9	11
294	Human papillomavirus infection among 100 oesophageal cancer cases in the People's Republic of China. <i>International Journal of Cancer</i> , 2007, 121, 1396-1398.	2.3	11
295	Application of a Novel, Rapid, and Sensitive Oligonucleotide Ligation Assay for Detection of Cancer-Predicting Mutations in the Precore and Basal Core Promoter of Hepatitis B Virus. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2723-2730.	1.8	11
296	Association of prediagnostic physical activity with survival following breast cancer diagnosis: influence of TP53 mutation status. <i>Cancer Causes and Control</i> , 2013, 24, 2177-2186.	0.8	11
297	Downregulation of transcription factor E4F1 in hepatocarcinoma cells: HBV-dependent effects on autophagy, proliferation and metabolism. <i>Carcinogenesis</i> , 2014, 35, 635-650.	1.3	11
298	Extracellular vesicles from myelodysplastic mesenchymal stromal cells induce DNA damage and mutagenesis of hematopoietic stem cells through miRNA transfer. <i>Leukemia</i> , 2020, 34, 2249-2253.	3.3	11
299	Hormonal Therapy and Risk of Breast Cancer in Mexican Women. <i>PLoS ONE</i> , 2013, 8, e79695.	1.1	11
300	Breast-cancer stromal cells with TP53 mutations. <i>New England Journal of Medicine</i> , 2008, 358, 1635-6; author reply 1636.	13.9	11
301	Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 912-919.	1.5	10
302	SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk. <i>Cancer Discovery</i> , 2022, 12, 2158-2179.	7.7	10
303	Among the human antibodies reacting with intracytoplasmic particles of mouse mammary tumor virus, some react with MMTV p14, the nucleic-acid-binding protein, and others with MMTV p28, the main core protein. <i>International Journal of Cancer</i> , 1983, 32, 27-35.	2.3	9
304	Efficient hepatitis C antigen immunohistological staining in sections of normal, cirrhotic and tumoral liver using a new monoclonal antibody directed against serum-derived HCV E2 glycoproteins. <i>Cancer Letters</i> , 2007, 248, 81-88.	3.2	9
305	Cancer Diagnostic and Predictive Biomarkers 2016. <i>BioMed Research International</i> , 2017, 2017, 1-2.	0.9	9
306	Effects of insulin, insulin-like growth factor-I (IGF-I) and progesterone on glucose and amino acid uptake in <i>Xenopus laevis</i> oocytes. <i>Molecular and Cellular Endocrinology</i> , 1991, 75, 133-139.	1.6	8

#	ARTICLE	IF	CITATIONS
307	Quantitation of p53 nuclear relocation in response to stress using a yeast functional assay: effects of irradiation and modulation by heavy metal ions. <i>Oncogene</i> , 2005, 24, 6459-6464.	2.6	8
308	Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo. <i>Journal of Gene Medicine</i> , 2005, 7, 936-944.	1.4	8
309	Somatic mutations in human cancer: applications in molecular epidemiology. <i>Revue D'Epidemiologie Et De Sante Publique</i> , 2005, 53, 257-266.	0.3	8
310	Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p. <i>PLoS ONE</i> , 2015, 10, e0143262.	1.1	8
311	Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia. <i>Hepatitis Research and Treatment</i> , 2011, 2011, 1-10.	2.0	6
312	TP53 Targeted Deep Sequencing of Cell-Free DNA in Esophageal Squamous Cell Carcinoma Using Low-Quality Serum: Concordance with Tumor Mutation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5627.	1.8	6
313	Cancer prevention and control: hepatocellular carcinoma. <i>Ecancermedalscience</i> , 2019, 13, 949.	0.6	5
314	Characterising obstructive sleep apnea patients through complex networks. <i>Chaos, Solitons and Fractals</i> , 2019, 119, 196-202.	2.5	5
315	Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown) Tj ETQq1 1 0.784314 rgBT ₄ /Overlo	1.1	4
316	TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations. <i>Hepatitis Research and Treatment</i> , 2011, 2011, 1-6.	2.0	4
317	TP53: Coordinator of the Processes That Underlie the Hallmarks of Cancer. , 2013, , 1-23.		4
318	Patterns of Benign and Malignant Lesions of the Thyroid in Two Wilayahs of Northeastern Algeria. <i>Journal of Cancer Epidemiology</i> , 2015, 2015, 1-5.	0.5	4
319	Changes in the pattern of breast cancer burden among African American women: evidence based on 29 states and District of Columbia during 1998 to 2010. <i>Annals of Epidemiology</i> , 2015, 25, 15-25.e10.	0.9	4
320	Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection. , 2007, , 293-319.		4
321	Molecular alchemy of the tumor suppressor protein p53: Metals and cell growth control. <i>Journal of Trace Elements in Experimental Medicine</i> , 1999, 12, 337-346.	0.8	3
322	Exposure to Hazardous Substances in a Standard Molecular Biology Laboratory Environment: Evaluation of Exposures in IARC Laboratories. <i>Annals of Occupational Hygiene</i> , 2009, 53, 485-90.	1.9	3
323	Evaluation of Tumorigenic Risk of Tissue-Engineered Oral Mucosal Epithelial Cells by Using Combinational Examinations. <i>Cell Transplantation</i> , 2010, 19, 999-1006.	1.2	3
324	p53 in metabolism, aging and cancer. <i>Annales De Dermatologie Et De Venereologie</i> , 2014, 141, S200-S201.	0.5	3

#	ARTICLE	IF	CITATIONS
325	Ten Years of Experience in Training Biobank Managers at Master's Level in France. , 2021, , 135-151.		3
326	Tumor-specific mutation spectra in the human p53 gene: From carcinogen "fingerprints" to functional consequences. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 1998, 16, 31-45.	2.9	2
327	Loss of TP53-DNA interaction induced by p.C135R in lung cancer. Oncology Reports, 2007, , .	1.2	2
328	Editorial foreword special issue "Hepatocellular Carcinoma" A Worldwide Translational Approach. Cancer Letters, 2009, 286, 3-4.	3.2	2
329	Biomarkers in cancer research and treatment: promises and challenges. Current Opinion in Oncology, 2011, 23, 61.	1.1	2
330	Molecular Signatures of Environmental Mutagens in Hepatocellular Carcinoma. Genes and Environment, 2011, 33, 141-148.	0.9	2
331	Loss of TP53-DNA interaction induced by p.C135R in lung cancer. Oncology Reports, 2007, 18, 1213-7.	1.2	2
332	Mouse mammary tumor virus (MMTV) infection in SWISS and RIII mice. Archives of Virology, 1990, 113, 35-52.	0.9	1
333	Response to "Germline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni-like syndrome", by Ribeiro et al.. Cancer Letters, 2007, 247, 356-358.	3.2	1
334	Response to: Concern regarding classification of germline TP53 variants as likely pathogenic. Human Mutation, 2019, 40, 832-833.	1.1	1
335	Editorial: Dissecting the pathological bone marrow niche through single-cell omics and artificial intelligence. Current Opinion in Oncology, 2020, 32, 137-138.	1.1	1
336	Editorial: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), COVID-19 and cancer: three research questions casting a long shadow. Current Opinion in Oncology, 2021, 33, 146-148.	1.1	1
337	Ethical Challenges for Biobanks: Two Sides of the Coin. , 2021, , 107-134.		1
338	TP53 Mutations in Human Cancers: Selection versus Mutagenesis. Molecular Biology Intelligence Unit, 2010, , 1-18.	0.2	1
339	Cancers of the Intestine, Liver, and Biliary Tract. , 2014, , 127-137.		1
340	IARC TP53 Database. , 2011, , 1799-1802.		1
341	ADN circulant : une source d'information pour la d�tection et le suivi du cancer.. Medecine/Sciences, 2000, 16, 446.	0.0	1
342	Introduction to the molecular genetics of cancer (molecular medical science series). Trends in Cell Biology, 1992, 2, 350-351.	3.6	0

#	ARTICLE	IF	CITATIONS
343	The origin of G to T transversions in lung cancer cell lines Reply to Rodin and Rodin. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 545, 145-146.	0.4	0
344	TP53: A master gene in normal and tumor suppression. , 0, , 233-244.		0
345	The geneticâ€œmetabolic duality of cancer. Current Opinion in Oncology, 2014, 26, 62-63.	1.1	0
346	Cancer Diagnostic and Predictive Biomarkers 2015. BioMed Research International, 2015, 2015, 1-1.	0.9	0
347	More chinks in the armor of cancer: potential for new therapies. Current Opinion in Oncology, 2017, 29, 33-34.	1.1	0
348	The Future of Biobanking: Meeting Tomorrowâ€™s Challenges. , 2021, , 187-197.		0
349	Inherited Pediatric Cancer in Low- and Intermediate-Resource Countries. , 2021, , 361-386.		0
350	Patterns of TP53 Mutations in Cancers of the Esophagus and Esophagogastric Junction: Correlation with Risk Factors and Functional Implications. , 2002, , 159-168.		0
351	TP63, TP73: The Guardianâ€™s Elder Brothers. Molecular Biology Intelligence Unit, 2010, , 36-52.	0.2	0
352	Abstract 1120: Low prevalence of TP53 mutations in pediatric rhabdomyosarcoma. , 2010, , .		0
353	Abstract 2995: MicroRNA expression and outcome of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program (IALT-Bio). , 2010, , .		0
354	Li-Fraumeni Syndrome. , 2011, , 2035-2039.		0
355	Abstract 1836: Distinct tumor spectrum and age of onset in a Brazilian cohort of p.R337H TP53 mutation carriers. , 2011, , .		0
356	Abstract 5538: Sarcomas in TP53 germline mutation carriers. , 2011, , .		0
357	Abstract 5349: Cancer stem cells isolation and characterization from breast tumor of a germline carrier of TP53 p.R337H (Brazilian founder) mutation. , 2012, , .		0
358	Abstract 3771: Establishment of primary cultures of cancer stem cells from patients with Li-Fraumeni Syndrome, carrier of TP53 p.R337H Brazilian founder mutation.. , 2013, , .		0
359	Li-Fraumeni Syndrome. , 2015, , 1-7.		0
360	Abstract 4468: Targeted deep sequencing of plasma circulating cell-free DNA shows VIM and FBLN1 methylation as potential biomarkers for hepatocellular carcinoma. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
361	Abstract A44: Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. , 2016, , .		0
362	Li-Fraumeni Syndrome. , 2017, , 2486-2492.		0
363	Abstract 4282: GermlineTP53p.R337H mutations and Li-Fraumeni syndrome: A new variant form of the disease. , 2017, , .		0
364	Cancers of the Intestine, the Liver, and the Biliary Tract. , 2020, , 179-191.		0
365	Editorial: Chromatin dynamics and immunosurveillance â€“ two sides of the cancer â€“cell identity crisisâ€™™. Current Opinion in Oncology, 2022, 34, 139-140.	1.1	0
366	Patterns of TP53 Mutations in Human Cancer: Interplay between Mutagenesis, DNA Repair and Selection. , 2007, , 293-319.		0
367	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. , 2007, , 321-338.		0